Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Relief Therapeutics Holding SA RLFTF

Healthcare Biotechnology
Relief Therapeutics Holding SA is a based drug development company focusing on clinical stage projects, primarily developing drugs of natural human origin. It is engaged in its operations for diabetic complications and respiratory diseases. The company is focused on developing drug candidates namely, Aviptadil and Atexakin alfa. Aviptadil is a biologically active endogenous human peptide that possesses anti-proliferative, anti-inflammatory, and immune regulatory activities. Atexakin alfa is a low dosage formulation of interleukin-6 that exhibits functions in diverse tissues and organs. The group operates its functions in Switzerland.


Recent & Breaking News (OTCQB:RLFTF)

NeuroRx Announced that RLF-100(TM) has Demonstrated Ten-Day Accelerated Recovery from Respiratory Failure among Patients with Severe Covid-19 Treated with HFNO at 28 Day Interim Endpoint

Accesswire February 24, 2021

NeuroRx Announces that ZYESAMI(TM) (Aviptadil) has Successfully Demonstrated 10-Day Accelerated Recovery from Respiratory Failure in Critically Ill Patients with Covid-19 Treated with High Flow Nasal Oxygen at 28-Day Interim Endpoint

PR Newswire February 23, 2021

NeuroRx reports Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI(TM) (aviptadil) in Reducing Hospital Stay among Patients with Respiratory Failure due to Critical COVID-19

PR Newswire February 9, 2021

NeuroRx and Relief Therapeutics Report Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI(TM) in Reducing Hospital Stay Among Patients with Respiratory Failure due to Critical COVID-19

PR Newswire February 9, 2021

Relief Announces Resignation of Thomaz Burckhardt as Member of the Board of Directors

Accesswire February 9, 2021

Relief Affirms Initiation of Phase 2/3 Trial of Inhaled RLF-100(TM) (Aviptadil; ZYESAMI(TM)) in Severe COVID-19 Patients

Accesswire February 8, 2021

Relief Therapeutics and Acer Therapeutics Sign Option Agreement for Exclusivity to Negotiate a Collaboration and License Agreement for the Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease

GlobeNewswire January 25, 2021

Relief Therapeutics and Acer Therapeutics Sign Option Agreement for Exclusivity to Negotiate a Collaboration and License Agreement for the Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease

Accesswire January 25, 2021

Relief Announces Implementation of New Share Subscription Facility with Main Shareholder GEM

Accesswire January 21, 2021

NeuroRx, Relief, and Quantum Leap announce the inclusion of ZYESAMI(TM) (RLF-100(TM): aviptadil) in the I-SPY COVID-19 Trial

PR Newswire January 11, 2021

NeuroRx and Relief Conclude Enrollment in their Phase 2b/3 Trial of RLF-100(TM) for Critical COVID-19 with Respiratory Failure

PR Newswire December 30, 2020

Relief Appoints Chris L.J.J. Stijnen as Chief Commercial Officer

Accesswire December 21, 2020

Relief Announces Results of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding AG Approved with Large Majority

Accesswire December 18, 2020

NeuroRx and Relief Therapeutics Meet 165 Patient Enrollment Target in Phase 2b/3 Trial of RLF-100(TM) for Critical COVID-19 with Respiratory Failure

PR Newswire December 7, 2020

CORRECTION: NeuroRx and Relief Announce Initial Successful Results from Expanded Access Use of RLF-100(TM) (aviptadil) in Patients with Critical COVID-19 and Severe Comorbidity: 72% Survival Seen in ICU Patients

Accesswire November 25, 2020

NeuroRx and Relief announce initial successful results from expanded access use of RLF-100(TM) (aviptadil) in patients with Critical COVID-19 and Severe Comorbidity: 72% survival seen in ICU patients

PR Newswire November 24, 2020

Relief Announces Notice of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding AG

Accesswire November 23, 2020

Relief Selects CRO and CDMO for RLF-100TM in Europe

Accesswire November 18, 2020

NeuroRx and Relief Therapeutics announce enrollment of 150 patients in phase 2b/3 trial of RLF-100(TM) for Critical COVID-19 with Respiratory Failure

PR Newswire November 13, 2020

Relief, with Partner NeuroRx, Announces Enrollment of 150 Patients in Phase 2b/3 Trial of RLF-100(TM) for Critical COVID-19 with Respiratory Failure

Accesswire November 13, 2020